Metis Global Partners LLC Sells 929 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Metis Global Partners LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 4,637 shares of the biopharmaceutical company’s stock after selling 929 shares during the period. Metis Global Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $1,512,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after buying an additional 185,783 shares during the last quarter. American Century Companies Inc. increased its holdings in Alnylam Pharmaceuticals by 9.8% in the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock worth $475,353,000 after buying an additional 156,411 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock worth $441,462,000 after buying an additional 162,121 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the transaction, the executive vice president owned 20,221 shares in the company, valued at approximately $9,129,377.08. This trade represents a 13.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last 90 days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $441.70 on Tuesday. The stock has a market cap of $58.35 billion, a P/E ratio of -178.83 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock’s fifty day moving average is $458.65 and its 200 day moving average is $379.32. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. During the same quarter in the prior year, the business posted ($0.50) earnings per share. The business’s quarterly revenue was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. UBS Group increased their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Twenty-three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $478.67.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.